Protective Effect of Ganshuang Granules () on Liver Cirrhosis by Suppressing Regulatory T Cells in Mouse Model.
10.1007/s11655-015-2430-9
- Author:
Yan-Min LIU
1
;
Hong-Bo SHI
1
;
Yi-Rong LIU
2
;
Hong-Lin SHI
1
;
Feng REN
1
;
Yu CHEN
3
;
De-Xi CHEN
1
;
Jin-Li LOU
4
;
Zhong-Ping DUAN
5
,
6
Author Information
1. Department of Liver Diseases Immunology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
2. Department of Toxic Hepatic Disease, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
3. Artifical Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
4. Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
5. Artifical Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. duan2517@
6. com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Ganshuang Granules;
hepatic stellate cell;
liver cirrhosis;
regulatory T cell
- MeSH:
Animals;
Disease Models, Animal;
Drugs, Chinese Herbal;
pharmacology;
therapeutic use;
Hepatic Stellate Cells;
drug effects;
Liver Cirrhosis, Experimental;
drug therapy;
immunology;
Male;
Mice;
Mice, Inbred BALB C;
T-Lymphocytes, Regulatory;
drug effects
- From:
Chinese journal of integrative medicine
2019;25(1):51-58
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the potential antifibrotic mechanisms of Chinese medicine Ganshuang Granules (, GSG) and to provide clinical therapeutic evidence of its effects.
METHODS:A cirrhotic mouse model was established by intraperitoneally injecting a mixture of CCl (40%) and oil (60%) at 0.2 mL per 100 g of body weight twice a week for 12 weeks. After 12-week modeling, GSG was intragastric administrated to the mice for 2 weeks, and the mice were divided into low-, medium- and high-dose groups at doses of 1, 2 and 4 g/(kg·day), respectively. Liver morphology changes were observed using Masson's trichrome staining and B-ultrasound. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and hyaluronic acid (HA) in serum were detected using an automatic biochemistry analyzer. The expressions of desmin, smooth muscle actin (SMA) and Foxp3 in liver were detected by immunoflfluorescence. The regulatory T cell (Treg) frequency was determined through flflow cytometry analysis. Collagen-I, SMA, IL-6, tumor necrosis factor α (TNF-α), interleukin (IL)-1β and transforming growth factor β1 (TGF-β1) expression levels were measured using quantitative polymerase chain reaction (qPCR).
RESULTS:Masson's staining result showed fewer pseudolobule structures and fibrous connective tissue in the GSG-treatment groups than in the spontaneous recovery group. Ultrasonography showed that GSG treatment reduced the number of punctate hyperechoic lesions in mice cirrhotic livers. The serum ALT, AST, HA levels were significantly ameliorated by GSG treatment (ALT: F=8.104, P=0.000; AST: F=7.078, P=0.002; and HA: F=7.621, P=0.001). The expression levels of collagen-I and SMA in the cirrhotic livers were also attenuated by GSG treatment (collagen-I: F=3.938, P=0.011; SMA: F=4.115, P=0.009). Tregs, which were elevated in the fibrotic livers, were suppressed by GSG treatment (F=8.268, P=0.001). The expressions of IL-6, TNF-α and IL-1β increased, and TGF-β levels decreased in the cirrhotic livers after GSG treatment (IL-6: F=5.457, P=0.004; TNF-α: F=6.023, P=0.002; IL-1β: F=6.658, P=0.001; and TGF-β1: F=11.239, P=0.000).
CONCLUSIONS:GSG promoted the resolution/regression of cirrhosis and restored liver functions in part by suppressing Treg cell differentiation, which may be mediated by hepatic stellate cells.
